NCT02299414

Brief Summary

The purpose of this study is to evaluate whether a blood pressure treatment strategy during pregnancy to achieve targets that are recommended for non-pregnant reproductive-age adults (\<140/90 mmHg) compared ACOG- recommended standard during pregnancy (no treatment unless BP is severe) is effective and safe.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,408

participants targeted

Target at P75+ for phase_4 hypertension

Timeline
Completed

Started Jun 2015

Longer than P75 for phase_4 hypertension

Geographic Reach
1 country

72 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 28, 2014

Completed
27 days until next milestone

First Posted

Study publicly available on registry

November 24, 2014

Completed
6 months until next milestone

Study Start

First participant enrolled

June 1, 2015

Completed
6.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2022

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 16, 2022

Completed
5 months until next milestone

Results Posted

Study results publicly available

May 17, 2023

Completed
Last Updated

May 17, 2023

Status Verified

May 1, 2023

Enrollment Period

6.8 years

First QC Date

October 28, 2014

Results QC Date

April 4, 2023

Last Update Submit

May 16, 2023

Conditions

Keywords

PregnancyChronic hypertension

Outcome Measures

Primary Outcomes (2)

  • Composite Adverse Perinatal Outcome

    One or more severe outcomes including fetal death or neonatal death up to discharge or 90 days if prior; preeclampsia with severe features up to 2 weeks postpartum (Severe hypertension and proteinuria or hypertension and severe features per ACOG); placental abruption; or indicated PTB \<35 weeks (not due to spontaneous preterm labor or membrane rupture).

    Up to 2 weeks postpartum for preeclampsia or 90 days for neonatal death

  • Small for Gestational Age (Safety)

    Birth weight less than 10th percentile for gestational age at birth according to accepted national standard

    Until delivery

Secondary Outcomes (5)

  • Composite of Maternal Death or Severe Cardiovascular Morbidity

    Up to 6 weeks (4-12 weeks) after delivery

  • Severe Maternal Hypertension + Components of the Primary Composite Endpoint

    Up to 2 weeks postpartum or 90 days for neonatal death

  • Preterm Birth and Indicated Preterm Birth (<37 Weeks)

    Until delivery

  • Composite of Severe Neonatal Morbidities

    Up to 90 days post delivery

  • Adherence to Treatment After Delivery

    6 weeks (4-12 weeks) after delivery

Other Outcomes (26)

  • Superimposed Preeclampsia

    Up to 2 weeks after delivery

  • Superimposed Gestational Hypertension

    Enrollment (between 6 and 18 weeks gestation) to delivery

  • Severe Hypertension

    Up to 6 weeks (4-12 weeks) after delivery

  • +23 more other outcomes

Study Arms (2)

Anti-hypertensive therapy to goal <140/90 mmHg

EXPERIMENTAL

Labetalol or Nifedipine ER will be used as first-line to achieve goal; if necessary Nifedipine ER or Labetalol will be second-line antihypertensive. Rarely, other antihypertensive medications may also be used

Drug: Anti-hypertensive therapy

No anti-hypertensive unless BP is severe (≥160/105 mmHg

ACTIVE COMPARATOR

Antihypertensive therapy given only if BP becomes severe (defined as BP ≥160/105). The lowest dose of anti-hypertensive needed to keep blood pressure below this threshold will be given (1st-line - Labetalol or Nifedipine ER and 2nd-line - Labetalol or Nifedipine ER). Rarely other medications may be used

Other: No anti-hypertensive therapy (unless BP is severe)

Interventions

1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)

Also known as: Normodyne, Trandate, Procardia XL, Adalat
Anti-hypertensive therapy to goal <140/90 mmHg

Treatment will not be started if blood pressure remains \<160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.

No anti-hypertensive unless BP is severe (≥160/105 mmHg

Eligibility Criteria

Age12 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Women with chronic hypertension in pregnancy with new or untreated chronic hypertension, blood pressure 140-159 systolic or 90-104 diastolic OR known chronic hypertension on monotherapy and taking any antihypertensive and blood pressure ≤159/104 (including those with blood pressure \<140/90);
  • Singleton; and
  • viable pregnancy \<23 weeks of gestation.

You may not qualify if:

  • Blood pressures prior to randomization ≥160 systolic or ≥105 diastolic (with or without treatment);
  • Severe hypertension including patients currently treated with \>1 antihypertensive medication (more likely to have severe chronic hypertension);
  • Multi-fetal pregnancy;
  • Known secondary cause of chronic hypertension;
  • High-risk co-morbidities for which treatment may be indicated:
  • Diabetes mellitus diagnosed at age ≤10 years or duration of diagnosis ≥20 years
  • Diabetes mellitus complicated by end organ damage (retinopathy, nephropathy, heart disease, transplant)
  • Chronic kidney disease - including baseline proteinuria (\>300mg/24-hr, protein/creatinine ratio ≥0.3, or persistent 1+ proteinuria\*) or creatinine \>1.2.
  • \*If a dipstick value at screening is more than trace, a clean catch or catheter urine should be obtained and re-tested by dipstick. If this shows trace or absence of protein, the patient is included. If it again shows 1+ protein, the patient is excluded until a 24-hr urine \<300mg/24hr or p/c ratio is \<0.3. If a p/c ratio is \>0.3, the patient may be included if a 24-hour urine is \< 300 mg.
  • Cardiac disorders: cardiomyopathy, angina, CAD
  • Prior stroke
  • Retinopathy
  • Sickle cell disease
  • Known major fetal anomaly;
  • Known fetal demise;
  • +8 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (72)

University of Alabama at Birmingham, Clinical Coordinating Center

Birmingham, Alabama, 35294, United States

Location

University of Alabama at Birmingham, Data Coordinating Center

Birmingham, Alabama, 35294, United States

Location

University of South Alabama

Mobile, Alabama, 36604, United States

Location

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States

Location

Arrowhead Regional Medical Center

Colton, California, 92324, United States

Location

University of California, San Diego

San Diego, California, 92110, United States

Location

General Hospital of San Francisco

San Francisco, California, 94110, United States

Location

University of California San Francisco

San Francisco, California, 94143, United States

Location

Stanford University

Stanford, California, 94305, United States

Location

University of Colorado

Boulder, Colorado, 80204, United States

Location

Denver Health

Denver, Colorado, 80204, United States

Location

Yale University

New Haven, Connecticut, 06511, United States

Location

Christiana Care Health Services

Newark, Delaware, 19713, United States

Location

University of South Florida

Tampa, Florida, 33606, United States

Location

Emory University

Atlanta, Georgia, 30322, United States

Location

Northwestern

Evanston, Illinois, 60208, United States

Location

Indiana University

Bloomington, Indiana, 47405, United States

Location

University of Iowa

Iowa City, Iowa, 52242, United States

Location

University of Kansas Medical Center

Lawrence, Kansas, 66045, United States

Location

University of Kentucky

Lexington, Kentucky, 40536, United States

Location

Tulane

New Orleans, Louisiana, 70112, United States

Location

Ochsner Health System/Medical Center

New Orleans, Louisiana, 70115, United States

Location

Beaumont Hospital

Royal Oak, Michigan, 48073, United States

Location

University of Mississippi Medical College

Jackson, Mississippi, 39216, United States

Location

Washington University

St Louis, Missouri, 63110, United States

Location

Robert Wood Johnson Medical School

New Brunswick, New Jersey, 08901, United States

Location

St. Peters University Hospital

New Brunswick, New Jersey, 08901, United States

Location

New Jersey Medical School

Newark, New Jersey, 07103, United States

Location

Virtua Medical Group

Sewell, New Jersey, 08080, United States

Location

New York Presbyterian Queens

Flushing, New York, 11355, United States

Location

Winthrop University Hospital

Mineola, New York, 11501, United States

Location

Columbia University

New York, New York, 10032, United States

Location

Weill Cornell

New York, New York, 10065, United States

Location

University of North Carolina

Chapel Hill, North Carolina, 27599, United States

Location

Duke Regional Medical Center

Durham, North Carolina, 27704, United States

Location

Duke University

Durham, North Carolina, 27705, United States

Location

WakeMed

Raleigh, North Carolina, 27610, United States

Location

TriHealth, Inc

Cincinnati, Ohio, 45220, United States

Location

Case Western/Metro Health

Cleveland, Ohio, 44109, United States

Location

Cleveland Clinic Fairview

Cleveland, Ohio, 44111, United States

Location

Ohio State University

Columbus, Ohio, 43210, United States

Location

Miami Valley Hospital

Dayton, Ohio, 45409, United States

Location

Cleveland Clinic-Hillcrest Hospital

Mayfield Heights, Ohio, 44124, United States

Location

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

Location

Oregon Health & Science University

Portland, Oregon, 97239, United States

Location

Lehigh Valley Hospital/Health Network

Allentown, Pennsylvania, 18101, United States

Location

St. Luke's University Health Network

Bethlehem, Pennsylvania, 18015, United States

Location

Geisinger Clinic

Danville, Pennsylvania, 17822, United States

Location

Drexel University College of Medicine

Philadelphia, Pennsylvania, 19019, United States

Location

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Pennsylvania Hospital

Philadelphia, Pennsylvania, 19104, United States

Location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Temple University

Philadelphia, Pennsylvania, 19140, United States

Location

University of Pittsburg/Magee Women's Center

Pittsburgh, Pennsylvania, 15201, United States

Location

Brown (WIHRI)

Providence, Rhode Island, 02912, United States

Location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

University of Tennessee Health Science Center

Memphis, Tennessee, 38103, United States

Location

Vanderbilt University

Nashville, Tennessee, 37232, United States

Location

UT Southwestern

Dallas, Texas, 75390, United States

Location

UT Medical Branch

Galveston, Texas, 77555, United States

Location

Baylor College of Medicine

Houston, Texas, 77030, United States

Location

UT Houston

Houston, Texas, 77030, United States

Location

McKay Dee Hospital

Ogden, Utah, 84403, United States

Location

Utah Valley Regional Medical Center

Provo, Utah, 84604, United States

Location

Intermountain Healthcare

Salt Lake City, Utah, 84132, United States

Location

University of Utah

Salt Lake City, Utah, 84132, United States

Location

LDS Hospital

Salt Lake City, Utah, 84143, United States

Location

Gundersen Health System

La Crosse, Wisconsin, 54601, United States

Location

Unity Point Health-Meriter Hospital

Madison, Wisconsin, 53715, United States

Location

Marshfield Clinic

Marshfield, Wisconsin, 54449, United States

Location

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Location

Aurora Research Institute

Milwaukee, Wisconsin, 53233, United States

Location

Related Publications (5)

  • Sanusi AA, Leach J, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Aagaard K, Edwards RK, Gibson KS, Haas DM, Plante L, Metz TD, Casey B, Esplin S, Longo S, Hoffman MK, Saade GR, Hoppe KK, Foroutan J, Tuuli M, Owens MY, Simhan HN, Frey H, Rosen T, Palatnik A, Baker S, August P, Reddy UM, Su EJ, Krishna I, Nguyen NA, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Galis ZS, Harper L, Ambalavanan N, Geller NL, Kuo HC, Sinkey RG, Librizzi R, Pereira L, Magann EF, Habli M, Williams S, Mari G, Pridjian G, McKenna DS, Parrish M, Eugene Chang, Osmundson S, Quinones J, Szychowski JM, Tita ATN. Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension. Obstet Gynecol. 2024 Jul 1;144(1):126-134. doi: 10.1097/AOG.0000000000005613. Epub 2024 May 23.

  • Moore MD, Kuo HC, Sinkey RG, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Aagaard K, Edwards RK, Gibson KS, Haas DM, Plante L, Metz TD, Casey B, Esplin S, Longo S, Hoffman MK, Saade GR, Hoppe KK, Foroutan J, Tuuli M, Owens MY, Simhan HN, Frey HA, Rosen T, Palatnik A, Baker S, August P, Reddy UM, Kinzler W, Su EJ, Krishna I, Nguyen NA, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Librizzi R, Pereira L, Magann EF, Habli M, Williams S, Mari G, Pridjian G, McKenna DS, Parrish M, Chang E, Osmundson S, Quinones JN, Leach J, Sanusi A, Galis ZS, Harper L, Ambalavanan N, Szychowski JM, Tita ATN. Mean Arterial Pressure and Neonatal Outcomes in Pregnancies Complicated by Mild Chronic Hypertension. Obstet Gynecol. 2024 Jul 1;144(1):101-108. doi: 10.1097/AOG.0000000000005611. Epub 2024 May 23.

  • Bailey EJ, Tita ATN, Leach J, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Aagaard K, Edwards RK, Gibson K, Haas DM, Plante L, Metz TD, Casey BM, Esplin S, Longo S, Hoffman M, Saade GR, Foroutan J, Tuuli MG, Owens MY, Simhan HN, Frey HA, Rosen T, Palatnik A, Baker S, August P, Reddy UM, Kinzler W, Su EJ, Krishna I, Nguyen N, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Galis ZS, Harper L, Ambalavanan N, Oparil S, Kuo HC, Szychowski JM, Hoppe K. Perinatal Outcomes Associated With Management of Stage 1 Hypertension. Obstet Gynecol. 2023 Dec 1;142(6):1395-1404. doi: 10.1097/AOG.0000000000005410. Epub 2023 Sep 28.

  • Goulding AN, Antoniewicz L, Leach JM, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Edwards RK, Gibson K, Haas DM, Plante L, Metz TD, Casey B, Esplin S, Longo S, Hoffman M, Saade GR, Hoppe KK, Foroutan J, Tuuli M, Owens MY, Simhan HN, Frey H, Rosen T, Palatnik A, Baker S, Reddy UM, Kinzler W, Su E, Krishna I, Nguyen N, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Harper LM, Ambalavanan N, Oparil S, Szychowski JM, Tita AT; Chronic Hypertension and Pregnancy Trial Consortium. Breastfeeding initiation and duration among people with mild chronic hypertension: a secondary analysis of the Chronic Hypertension and Pregnancy trial. Am J Obstet Gynecol MFM. 2023 Sep;5(9):101086. doi: 10.1016/j.ajogmf.2023.101086. Epub 2023 Jul 10.

  • Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Aagaard K, Edwards RK, Gibson K, Haas DM, Plante L, Metz T, Casey B, Esplin S, Longo S, Hoffman M, Saade GR, Hoppe KK, Foroutan J, Tuuli M, Owens MY, Simhan HN, Frey H, Rosen T, Palatnik A, Baker S, August P, Reddy UM, Kinzler W, Su E, Krishna I, Nguyen N, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Galis ZS, Harper L, Ambalavanan N, Geller NL, Oparil S, Cutter GR, Andrews WW; Chronic Hypertension and Pregnancy (CHAP) Trial Consortium. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022 May 12;386(19):1781-1792. doi: 10.1056/NEJMoa2201295. Epub 2022 Apr 2.

MeSH Terms

Conditions

Hypertension

Interventions

LabetalolNifedipine

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsSalicylamidesAmidesAminesDihydropyridinesPyridinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Results Point of Contact

Title
Dr. Alan Tita
Organization
University of Alabama at Birmingham

Study Officials

  • Alan Tita, MD, PhD

    University of Alabama at Birmingham - Clinical Coordinating Center

    PRINCIPAL INVESTIGATOR
  • Gary Cutter, PhD

    University of Alabama at Birmingham-Data Coordinating Center

    PRINCIPAL INVESTIGATOR
  • Jeff Szychowski, PhD

    University of Alabama at Birmingham-Data Coordinating Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 28, 2014

First Posted

November 24, 2014

Study Start

June 1, 2015

Primary Completion

April 1, 2022

Study Completion

December 16, 2022

Last Updated

May 17, 2023

Results First Posted

May 17, 2023

Record last verified: 2023-05

Locations